View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
November 16, 2018

M&As this week: Nestle Health, InvaGen, Takeda

Nestle Health has acquired a 19% stake in Aimmune Therapeutics for $98m.

Nestle Health has acquired a 19% stake in Aimmune Therapeutics for $98m.

The companies have also extended a prior agreement for developing food allergy treatments by two years. The agreement allows Aimmune to retain all rights to its existing and future pipeline assets.

The deal has increased Nestle Health’s total investment in Aimmune to $273m.

Based in the US, Nestle Health is a health sciences company focused on nutrition therapy, while Aimmune is a clinical-stage biopharmaceutical company developing treatments for food allergies.

InvaGen has entered an agreement to acquire Avenue Therapeutics for $215m.

In the first stage of the transaction, InvaGen will acquire a 33.3% stake in Avenue’s capital stock for $35m priced at $6 a share.

The second stage will involve the purchase of all remaining Avenue shares for up to $180m priced at $13.92 a share.

InvaGen is subsidiary of India-based pharmaceutical company Cipla, while Avenue Therapeutics is a speciality pharmaceutical company based in the US.

“Asterias Biotherapeutics and BioTime have signed a merger agreement to form an integrated company that will focus on cell therapies.”

Takeda has set a date for an emergency general meeting (EGM) to vote on the acquisition of Shire for $62bn.

Takeda secured a loan of $31bn from JP Morgan, Sumitomo Mitsui Banking Corp, and MUFG Bank to fund the acquisition, which will take place only if two-thirds of Takeda’s shareholders support the deal at the EGM.

The deal has received the approval of Japanese, US, Brazilian and Chinese authorities.

Based in Japan, Takeda is a pharmaceutical company, while Shire is a speciality biopharmaceutical company based in the US.

Asterias Biotherapeutics and BioTime have signed a merger agreement to form an integrated company that will focus on cell therapies.

Following the transaction, BioTime will hold an 83.8% interest in the combined entity, while Asterias will hold the remaining 16.2%.

The merger agreement is expected to be closed in Q1 2019.

Asterias Biotherapeutics and BioTime are biotechnology companies based in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology